{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:09:41Z","timestamp":1790424581478,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We compared outcomes of 1461 adult patients with acute lymphoblastic leukemia (ALL) receiving hematopoietic cell transplantation (HCT) from a haploidentical (n = 487) or matched unrelated donor (MUD; n = 974) between January 2005 and June 2018. Graft-versus-host disease (GVHD) prophylaxis was posttransplant cyclophosphamide (PTCy), calcineurin inhibitor (CNI), and mycophenolate mofetil (MMF) for haploidentical, and CNI with MMF or methotrexate with\/without antithymoglobulin for MUDs. Haploidentical recipients were matched (1:2 ratio) with MUD controls for sex, conditioning intensity, disease stage, Philadelphia-chromosome status, and cytogenetic risk. In the myeloablative setting, day +28 neutrophil recovery was similar between haploidentical (87%) and MUD (88%) (P = .11). Corresponding rates after reduced-intensity conditioning (RIC) were 84% and 88% (P = .47). The 3-month incidence of grade II-IV acute GVHD (aGVHD) and 3-year chronic GVHD (cGVHD) was similar after haploidentical compared with MUD: myeloablative conditioning, 33% vs 34% (P = .46) for aGVHD and 29% vs 31% for cGVHD (P = .58); RIC, 31% vs 30% (P = .06) for aGVHD and 24% vs 29% for cGVHD (P = .86). Among patients receiving myeloablative regimens, 3-year probabilities of overall survival were 44% and 51% with haploidentical and MUD (P = .56). Corresponding rates after RIC were 43% and 42% (P = .6). In this large multicenter case-matched retrospective analysis, despite the limitations of a registry-based study (ie, unavailability of key elements such as minimal residual disease testing), our analysis indicated that outcomes of patients with ALL undergoing HCT from a haploidentical donor were comparable with 8 of 8 MUD transplantations.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001499","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T20:12:05Z","timestamp":1589314325000},"page":"2073-2083","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":56,"title":["Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr M.","family":"Al Malki","sequence":"first","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0736-4977","authenticated-orcid":false,"given":"Dongyun","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Computational Quantitative Medicine\u2013Beckman Research Institute, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"first","affiliation":[{"name":"Department of Hematology, European Society for Blood and Marrow Transplantation (EBMT) Paris Study Office\/Centros de Refer\u00eancia em Sa\u00fade do Trabalhador, H\u00f4pital Saint Antoine, INSERM, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Afanasyev","sequence":"first","affiliation":[{"name":"Raisa Gorbacheva Memorial Institute of Children Oncology, Hematology and Transplantation, St. Petersburg, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6512-6080","authenticated-orcid":false,"given":"Emanuele","family":"Angelucci","sequence":"first","affiliation":[{"name":"Ematologia e Centro Trapianti, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Policlinico San Martino, Genoa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Bashey","sequence":"first","affiliation":[{"name":"The Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Soci\u00e9","sequence":"first","affiliation":[{"name":"Department of Hematology\u2013Bone Marrow Transplantation (BMT), Hospital St. Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amado","family":"Karduss-Urueta","sequence":"first","affiliation":[{"name":"Bone Marrow Transplant Program, Instituto de Cancerologia\u2013Clinica Las Americas, Medellin, Colombia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3703-1268","authenticated-orcid":false,"given":"Grzegorz","family":"Helbig","sequence":"first","affiliation":[{"name":"Department of Hematology and Bone Marrow Transplantation, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bornhauser","sequence":"first","affiliation":[{"name":"University Hospital Carl Gustav Carus, Technische Universit\u00e4t Dresden, Dresden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Niittyvuopio","sequence":"first","affiliation":[{"name":"Stem Cell Transplantation Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"first","affiliation":[{"name":"Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"first","affiliation":[{"name":"Hematology and BMT Unit, San Raffaele Scientific Institute, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Brecht","sequence":"first","affiliation":[{"name":"Helios Dr. Horst Schmidt Kliniken Wiesbaden, Wiesbaden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yener","family":"Koc","sequence":"first","affiliation":[{"name":"Stem Cell Transplant Unit, Medical Park Hospitals, Antalya, Turkey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli","family":"Bejanyan","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology and Transplantation, University of Minnesota Medical Center, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ferraro","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Partow","family":"Kebriaei","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Mokhtari","sequence":"first","affiliation":[{"name":"Department of Clinical Translational Project Development, City of Hope National Medical Center, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Ghobadi","sequence":"first","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Forman","sequence":"first","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4314-5037","authenticated-orcid":false,"given":"Richard","family":"Champlin","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"first","affiliation":[{"name":"Department of Hematology, European Society for Blood and Marrow Transplantation (EBMT) Paris Study Office\/Centros de Refer\u00eancia em Sa\u00fade do Trabalhador, H\u00f4pital Saint Antoine, INSERM, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"first","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"first","affiliation":[{"name":"Department of Hematology, European Society for Blood and Marrow Transplantation (EBMT) Paris Study Office\/Centros de Refer\u00eancia em Sa\u00fade do Trabalhador, H\u00f4pital Saint Antoine, INSERM, Paris, France;"},{"name":"Hematology Division, BMT Department, Chaim Sheba Medical Center, Tel Hashomer, Israel; and"},{"name":"Acute Leukaemia Working Party, EBMT, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"6","key":"2020051211342446900_B1","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2008-07-168625","article-title":"Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison","volume":"113","author":"Cornelissen","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2020051211342446900_B2","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2020051211342446900_B3","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"issue":"20","key":"2020051211342446900_B4","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1200\/JCO.2004.10.050","article-title":"Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial","volume":"22","author":"Thomas","year":"2004","journal-title":"J Clin Oncol"},{"issue":"9","key":"2020051211342446900_B5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbmt.2007.06.001","article-title":"Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease","volume":"13","author":"Lee","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020051211342446900_B6","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2002-09-2866","article-title":"Hematopoietic stem cell transplantation: contrasting the outcome of transplantations from HLA-identical siblings, partially HLA-mismatched related donors, and HLA-matched unrelated donors","volume":"102","author":"Ottinger","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2020051211342446900_B7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2020051211342446900_B8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.bbmt.2011.08.001","article-title":"Progress in haploidentical stem cell transplantation","volume":"18","author":"Bayraktar","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020051211342446900_B9","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-3148.2008.00865.x","article-title":"Efforts of the United States\u2019 National Marrow Donor Program and Registry to improve utilization and representation of minority donors","volume":"18","author":"Johansen","year":"2008","journal-title":"Transfus Med"},{"key":"2020051211342446900_B10","doi-asserted-by":"crossref","first-page":"5726132","DOI":"10.1155\/2016\/5726132","article-title":"Review on haploidentical hematopoietic cell transplantation in patients with hematologic malignancies","volume":"2016","author":"Fabricius","year":"2016","journal-title":"Adv Hematol"},{"key":"2020051211342446900_B11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1182\/asheducation.V2012.1.230.3798312","article-title":"Haploidentical transplantation for hematologic malignancies: where do we stand?","volume":"2012","author":"Fuchs","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"2020051211342446900_B12","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.1997.15.5.1767","article-title":"Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings","volume":"15","author":"Szydlo","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020051211342446900_B13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2020051211342446900_B14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/bbmt.2002.v8.pm12171484","article-title":"Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide","volume":"8","author":"O\u2019Donnell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2020051211342446900_B15","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.bbmt.2012.07.003","article-title":"Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation","volume":"18","author":"Ciurea","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020051211342446900_B16","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.bbmt.2012.08.007","article-title":"Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies","volume":"19","author":"Ciurea","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"2020051211342446900_B17","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"2020051211342446900_B18","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2020051211342446900_B19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","article-title":"Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"103","author":"Salvatore","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"2020051211342446900_B20","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41409-019-0459-7","article-title":"Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed\/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT","volume":"54","author":"Battipaglia","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"38","key":"2020051211342446900_B21","doi-asserted-by":"crossref","first-page":"63574","DOI":"10.18632\/oncotarget.18862","article-title":"Similar outcomes after haploidentical transplantation with post-transplant cyclophosphamide versus HLA-matched transplantation: a meta-analysis of case-control studies","volume":"8","author":"Gu","year":"2017","journal-title":"Oncotarget"},{"issue":"12","key":"2020051211342446900_B22","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"2020051211342446900_B23","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.bbmt.2016.11.008","article-title":"Haploidentical transplantation with post-transplantation cyclophosphamide for high-risk acute lymphoblastic leukemia","volume":"23","author":"Srour","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2020051211342446900_B24","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-017-0480-5","article-title":"Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT","volume":"10","author":"Santoro","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2020051211342446900_B25","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41375-019-0544-3","article-title":"Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMT","volume":"34","author":"Shem-Tov","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"2020051211342446900_B26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020051211342446900_B27","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020051211342446900_B28","first-page":"250","article-title":"Chronic graft-versus-host disease and other late complications of bone marrow transplantation","volume":"28","author":"Sullivan","year":"1991","journal-title":"Semin Hematol"},{"issue":"408","key":"2020051211342446900_B29","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the Cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"2020051211342446900_B30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"issue":"2","key":"2020051211342446900_B31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10985-014-9313-9","article-title":"Checking Fine and Gray subdistribution hazards model with cumulative sums of residuals","volume":"21","author":"Li","year":"2015","journal-title":"Lifetime Data Anal"},{"issue":"26","key":"2020051211342446900_B32","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell-replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020051211342446900_B33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13045-018-0586-4","article-title":"Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT","volume":"11","author":"Ruggeri","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"4","key":"2020051211342446900_B34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/s41409-018-0367-2","article-title":"Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10\/10 HLA-matched unrelated donor hematopoietic stem cell transplantation","volume":"54","author":"Shah","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020051211342446900_B35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41409-017-0053-9","article-title":"Reduction of severe acute graft-versus-host disease using a combination of pre transplant anti-thymocyte globulin and post-transplant cyclophosphamide in matched unrelated donor transplantation","volume":"53","author":"Deotare","year":"2018","journal-title":"Bone Marrow Transplant"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/9\/2073\/1728696\/advancesadv2020001499.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/9\/2073\/1728696\/advancesadv2020001499.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T20:12:32Z","timestamp":1589314352000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/9\/2073\/455053\/Comparing-transplant-outcomes-in-ALL-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001499","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]}}}